A treatment that helps you take on the challenge
LUPKYNIS is helping to transform the way lupus nephritis is treated
Helps control lupus nephritis
In clinical trials, people who took LUPKYNIS as part of their treatment plan were about twice as likely to have their lupus nephritis under controla at 1 year of treatment than those only taking mycophenolate mofetil (also called MMF) and steroids.b
Lowered the dose of steroids needed
In clinical trials, LUPKYNIS helped to stop the attack of lupus nephritis with low-dose steroids.
Reduces protein in urine
In clinical trials, LUPKYNIS helped reduce protein in the urine (called proteinuria, a key sign of disease activity) roughly 2x fasterc than MMF and steroids alone.
People taking LUPKYNIS saw a 50% reduction of proteinuria, on average after just one month.
Studied across different races and ethnicities
LUPKYNIS was tested in clinical studies that involved more than 350 people across different races and ethnicities.
aControl was defined as reducing protein in the urine to ≤0.5 mg/mg, while helping maintain kidney function.
bAt 1 year, ~41% of people taking LUPKYNIS as part of their treatment plan had their lupus nephritis under control compared to ~23% of people taking only MMF and steroids.
cOn average after six months of treatment compared to a year for patients only taking MMF and steroids.
Feel confident talking to your doctor about LUPKYNIS
Our downloadable doctor discussion guide can help make starting the conversation easier.